Chromosome 1p and 19q Deletions in Glioblastoma Multiforme

被引:23
作者
Kaneshiro, David [2 ]
Kobayashi, Taisei [1 ]
Chao, Samuel T. [1 ]
Suh, John [1 ]
Prayson, Richard A. [1 ]
机构
[1] Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA
关键词
glioblastoma multiforme (GBM); fluorescent in situ hybridization (FISH); chromosome; 1p; 19q; PHASE-III TRIAL; ANAPLASTIC OLIGODENDROGLIOMAS; GENETIC ALTERATIONS; SURVIVAL; GLIOMAS; PREDICTORS; GENOTYPE; IMPACT; OLIGOASTROCYTOMAS; PROCARBAZINE;
D O I
10.1097/PAI.0b013e3181a2c6a4
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Context: Deletions on chromosomes 1p and 19q have been shown to correlate with prognosis and chemosensitivity in anaplastic oligodendrogliomas. In glioblastoma multiforme (GBM), the impact on prognosis of these alterations in GBM is unclear. Objective: The purpose of this study was to identify patients with GBM who had evidence of 1p or 19q deletions by flourescence in situ hybridization, and correlate these results with clinical findings and survival. Design: Three hundred thirty-seven GBM resected between 2001 and 2006 were evaluated using flourescence in situ hybridization to identify deletions on chromosomes 1p and 19q. Cox regression was used to compare survival between these 2 groups and a control group of 1p and 19q intact tumors. Result: Seventeen (5.1%) patients (9 males; mean age at diagnosis = 61y, range: 35 to 84y) were found to have 1p deletions; 8 patients (47.1%) received chemotherapy and 13 patients received radiation therapy. The mean survival for this group was 10.8 months (range: 1 to 50 mo). Eighteen (5.3%) patients (11 females; mean = 56 y, range: 25 to 76 y) had 19q deletions; 9 patients (50%) received chemotherapy and 8 patients were known to have had radiation therapy. The mean survival of this group was 8.4 months (range: 1 to 17 mo). A control group of 20 patients (13 males; mean = 60y, range: 40 to 80 y) was selected, 8 patients (40%) of who received chemotherapy and 12 patients were known to have had radiation therapy. The mean survival in this group was found to be 16.4 months (1 to 59 mo). Nine (3.7%) tumors had codeletions of 1p and 19q and were not evaluated in this study. Isolated 1p and 19q deletions did not significantly correlate with survival. Adjusting for sex, age, and chemotherapy, the 19q-deleted group had a significantly lower survival (hazard ratio = 2.8, P = 0.025) than the other groups. Conclusions: The incidence of isolated 1p or 19q deletions among GBM in the current study was 6.2% and 5.3%, respectively. In contrast to anaplastic oligodendrogliomas, 1p and 19q deletions alone were not found to improve survival of patients with GBM; however, when adjusted for age, sex, and chemotherapy, 19q deletions seem to negatively impact survival.
引用
收藏
页码:512 / 516
页数:5
相关论文
共 22 条
  • [1] Age-dependent prognostic effects of genetic alterations in glioblastoma
    Batchelor, TT
    Betensky, RA
    Esposito, JM
    Pham, LDD
    Dorfman, MV
    Piscatelli, N
    Jhung, S
    Rhee, D
    Louis, DN
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (01) : 228 - 233
  • [2] Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
    Bigner, SH
    Matthews, MR
    Rasheed, BKA
    Wiltshire, RN
    Friedman, HS
    Friedman, AH
    Stenzel, TT
    Dawes, DM
    McLendon, RE
    Bigner, DD
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) : 375 - 386
  • [3] Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities
    Buckner, JC
    Gesme, D
    O'Fallon, JR
    Hammock, JE
    Stafford, S
    Brown, PD
    Hawkins, R
    Scheithauer, BW
    Erickson, BJ
    Levitt, R
    Shaw, EG
    Jenkins, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 251 - 255
  • [4] Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
    Cairncross, Gregory
    Berkey, Brian
    Shaw, Edward
    Jenkins, Robert
    Scheithauer, Bernd
    Brachman, David
    Buckner, Jan
    Fink, Karen
    Souhami, Luis
    Laperierre, Normand
    Mehta, Minesh
    Curran, Walter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2707 - 2714
  • [5] Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
    Cairncross, JG
    Ueki, K
    Zlatescu, MC
    Lisle, DK
    Finkelstein, DM
    Hammond, RR
    Silver, JS
    Stark, PC
    Macdonald, DR
    Ino, Y
    Ramsay, DA
    Louis, DN
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) : 1473 - 1479
  • [6] Genetic markers in glioblastoma: Prognostic significance and future therapeutic implications - Commentary
    Hill, C
    Hunter, SB
    Brat, DJ
    [J]. ADVANCES IN ANATOMIC PATHOLOGY, 2003, 10 (04) : 212 - 217
  • [7] Correlation among pathology, genotype, and patient outcomes in glioblastoma
    Homma, Taku
    Fukushima, Takao
    Vaccarella, Salvatore
    Yonekawa, Yasuhiro
    Di Patre, Pier Luigi
    Franceschi, Silvia
    Ohgaki, Hiroko
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2006, 65 (09) : 846 - 854
  • [8] Prognostic impact of molecular markers in a series of 220 primary glioblastomas
    Houillier, C
    Lejeune, J
    Benouaich-Amiel, A
    Laigle-Donadey, F
    Criniere, E
    Mokhtari, K
    Thillet, J
    Delaffre, JY
    Hoang-Xuan, K
    Sanson, M
    [J]. CANCER, 2006, 106 (10) : 2218 - 2223
  • [9] 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas
    Ichimura, K.
    Vogazianou, A. P.
    Liu, L.
    Pearson, D. M.
    Backlund, L. M.
    Plant, K.
    Baird, K.
    Langford, C. F.
    Gregory, S. G.
    Collins, V. P.
    [J]. ONCOGENE, 2008, 27 (14) : 2097 - 2108
  • [10] Two types of chromosome 1p losses with opposite significance in gliomas
    Idbaih, A
    Marie, Y
    Pierron, G
    Brennetot, C
    Khê, HX
    Kujas, M
    Mokhtari, K
    Sanson, M
    Lejeune, J
    Aurias, A
    Delattre, O
    Delattre, JY
    [J]. ANNALS OF NEUROLOGY, 2005, 58 (03) : 483 - 487